Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.| JNJ.com
Learn more about Robert Zhao, Ph.D, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.| JNJ.com
Learn the latest about this common procedure and how Johnson & Johnson MedTech is innovating to improve patient outcomes.| JNJ.com
Candice Otrembiak's work combines her love of science with her natural problem-solving skills. The result: high-tech devices that help make medical procedures more efficient for surgeons and safer for patients.| JNJ.com
Inflammatory bowel disease doesn't have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.| JNJ.com
Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But a number of scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed what kind of prognosis many of these patients will have.| JNJ.com
What once seemed like an unattainable goal may soon be within our grasp. Learn how Johnson & Johnson is working toward its vision to create a world without cancer.| JNJ.com
A Johnson & Johnson scientist explains how the new Acuvue® Oasys Max 1-Day Multifocal for Astigmatism contact lens also filters blue light, supports the eye's natural tear film and helps eyes easily switch focus from distance to reading.| JNJ.com
After decades of commitment to understanding this neurodegenerative disease, company scientists have developed innovative therapies and tools that can potentially slow its progression and ease the psychological toll on patients and caretakers. A cure is still elusive—but preventing the disease may…| JNJ.com
Read all stories about Johnson & Johnson innovation| JNJ.com